Submit a comment
Citation Information: J Clin Invest. 1973;52(2):528-532. https://doi.org/10.1172/JCI107212.
Abstract
The administration of exogenous iodides (saturated solution of potassium iodide, SSKI) to normal male volunteers resulted in a significant decrease in the serum concentration of thyroxine (T4) and triiodothyronine (T3) and a significant increase in serum concentration of thyrotropin (TSH). During the control period (phase I), serum concentrations of T4 averaged 6.9±1.8 μg/100 ml (mean ±SD), T3 106±15 ng/100 ml, and TSH 3.7±1.3 μU/ml. During the administration of 1 drop of SSKI twice daily for 11 days (phase II), there was a small but significant decrease in the serum concentration of T4 and T3 (5.8±1.6 μg/100 ml and 91±19 ng/100 ml, respectively) and a small but significant increase in the serum concentration of TSH (6.0±3.5 μU/ml). During the administration of 5 drops of SSKI twice daily (phase III) over the following 12-19 days, these changes persisted, except for a small increase in the serum concentration of T3 (97±20 ng/100 ml), which was statistically significant when compared to values obtained during phase II. Values returned to control levels 14 days after withdrawal of SSKI. Almost all these observed changes took place within the limits of the normal range. It is postulated that, in euthyroid individuals, iodides specifically inhibit release of T4 and probably of T3. The resulting slight decrease in values for serum T4 and T3 elicits a small increase in TSH secretion which, it is postulated, antagonizes the inhibition of hormone release induced by iodides. As a result, a new equilibrium is reached which maintains the euthyroid state.
Authors
Apostolos G. Vagenakis, Patricia Downs, Lewis E. Braverman, Albert Burger, Sidney H. Ingbar
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)